Venture capital fund
Sydney, NSW
Every published round Start-up Australia Ventures took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Start-up Australia Ventures has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Start-up Australia Ventures, as distinct from the investments it has made.
Companies Start-up Australia Ventures has backed that another company then bought. An exit for the holding, not a deal Start-up Australia Ventures did.
Stories naming Start-up Australia Ventures. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
GBS Ventures' letter to Arana Therapeutics shareholders covers Cephalon's proposed cash takeover, an attached dividend, the board's recommendation to accept, and Cephalon's pre-bid purchase of a 19.8% stake.
Cephalon has announced plans to buy out Arana Therapeutics shareholders at $1.40 a share, potentially $1.45, valuing the ASX-listed target around $318 million; its independent directors back the bid unless a better one emerges.